Search results
Results from the WOW.Com Content Network
Activation of a wide range of serotonin receptors by serotonin itself or by certain prokinetic drugs results in enhanced gastrointestinal motility. [3] Other prokinetic drugs may increase acetylcholine concentrations by stimulating the M 1 receptor which causes acetylcholine release, or by inhibiting the enzyme acetylcholinesterase which ...
Motilin is a 22-amino acid polypeptide hormone in the motilin family that, in humans, is encoded by the MLN gene. [2]Motilin is secreted by endocrine Mo cells [3] [4] (also referred to as M cells, which are not the same as the M cells, or microfold cells, found in Peyer's patches) that are numerous in crypts of the small intestine, especially in the duodenum and jejunum. [5]
The increase in prolactin levels observed with the two drugs was much greater in women than in men. [ 74 ] [ 75 ] This appears to be due to the higher estrogen levels in women, as estrogen stimulates prolactin secretion from the pituitary gland .
Prucalopride is contraindicated where there is hypersensitivity to the active substance or to any of the excipients, renal impairment requiring dialysis, intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract, such as Crohn's disease, and ulcerative colitis and toxic megacolon ...
Generally, drugs outlined within the ATC code A should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Gastrointestinal system drugs .
Alpha blockers may increase GI motility if that is an issue, also 5 mg to 10 mg amitriptyline if motility is an issue that can't be solved by other methods; Antigas - simethicone, beano, omnimax reduces epigastric pressure
(Reuters) -Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not ...
Mosapride is a gastroprokinetic agent that acts as a selective 5HT 4 agonist.The major active metabolite of mosapride, known as M1, additionally acts as a 5HT 3 antagonist, [1] which accelerates emptying throughout the whole of the gastrointestinal tract in humans, [2] and is used for the treatment of gastritis, gastroesophageal reflux disease, functional dyspepsia [3] and irritable bowel ...